Malaria Vaccines Market
The Global Malaria Vaccines Market is estimated to be valued at USD 550.1 Mn in 2024 and is expected to reach USD 1,252.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031. Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected Anopheles mosquitoes. The currently available strategies for malaria prevention and control such as insecticide treated nets, spraying of insecticides and antimalarial drugs are proving insufficient to curb the spread of the disease. This makes malaria vaccines an urgent and vital public health tool to reduce malaria morbidity and mortality in endemic regions. Vaccines can provide long lasting immunity without requiring large healthcare infrastructure, thereby offering a cost-effective and sustainable solution towards malaria elimination goals.
Market Dynamics:
The global malaria vaccines market is primarily driven by the high disease burden of malaria worldwide, especially in African countries, massive funding for malaria vaccine development from global health organizations and growing acceptance of vaccines as an important public health intervention. However, technical challenges in developing an effective malaria vaccine owing to the complex life cycle of parasite Plasmodium and lack of comprehensive understanding of protective immune responses continue to restrain market potential. Meanwhile, ongoing advancements in vaccinology, immunology, and pathogen genomics have created opportunities for the development of novel vaccine design approaches and antigen targets. Further opportunities lie in expanding manufacturing capacity and ensuring successful uptake of malaria vaccines, once available, in malaria endemic populations through coordinated efforts of World Health Organization (WHO), Program for Appropriate Technology in Health, Malaria Vaccine Initiative (PATH MVI), and government immunization programs.
Key Features of the Study:
- This report provides in-depth analysis of the global malaria vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global malaria vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceuticals, Vaxart, Inc., and BioNTech SE
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global malaria vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global malaria vaccines market
Market Segmentation
Market Segmentation
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
